TrianglePUBLICATIONS · 37276871
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Lancet Oncol
- Publication date
- 2023 Jul
- First author
- Harding JJ
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Harding JJ
- type
- Author
- name
- Fan J
- type
- Author
- name
- Oh DY
- type
- Author
- name
- Choi HJ
- type
- Author
- name
- Kim JW
- type
- Author
- name
- Chang HM
- type
- Author
- name
- Bao L
- type
- Author
- name
- Sun HC
- type
- Author
- name
- Macarulla T
- type
- Author
- name
- Xie F
- type
- Author
- name
- Metges JP
- type
- Author
- name
- Ying J
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Harding JJ
- type
- Author
- name
- Fan J
- type
- Author
- name
- Oh DY
- type
- Author
- name
- Choi HJ
- type
- Author
- name
- Kim JW
- type
- Author
- name
- Chang HM
- type
- Author
- name
- Bao L
- type
- Author
- name
- Sun HC
- type
- Author
- name
- Macarulla T
- type
- Author
- name
- Xie F
- type
- Author
- name
- Metges JP
- type
- Author
- name
- Ying J
- type
- Author
- bibliography ids
- nci-bib-da7d8fbef2c572b9849084ae
- book metadata
- content sha256
- 5331c2cad30b08ec4e55e989ab2b94a98f0511cf97fd1a3748a0909582e86a3a
- document type
- citation
- dois
- 10.1016/S1470-2045(23)00242-5
- electronic publication date
- display
- 2023 Jun 2
- precision
- day
- year
- 2023
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:37276871
- immutable id
- pubmed:37276871@5331c2cad30b08ec4e55e989ab2b94a98f0511cf97fd1a3748a0909582e86a3a
- journal
- abbreviation
- Lancet Oncol
- issn electronic
- 1474-5488
- issn print
- 1470-2045
- issue
- 7
- name
- The Lancet. Oncology
- nlm unique id
- 100957246
- pages
- 772-782
- volume
- 24
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 37276871
- provenance
- batch id
- 5329a5d0877ee70ecd11
- provider
- NCBI PubMed ESummary
- record sha256
- 8014299e0af7a4871752ba52bf6e06af6c65aa4bac0b1d77649c52f3a0092853
- response sha256
- bcc4d4935bae07b2d0bf7ef24187cf1ff9d849601f315c9dbe2002bd5de6f631
- retrieved at
- 2026-09-09T23:48:15.763286+00:00
- publication date
- display
- 2023 Jul
- precision
- month
- year
- 2023
- publication types
- Clinical Trial, Phase II
- Journal Article
- Multicenter Study
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.
Preserved source evidence · Not medical advice